USV partners with Biogenomics to launch first biosimilar Insulin Aspart for diabetics In India

08 November 2023 | News

INSUQUICK is 100% Made in India with the potential to improve treatment access for people with diabetes

image credit- shutterstock

image credit- shutterstock

Mumbai-based USV Pvt Ltd and Biogenomics (based in Thane) have announced the launch of INSUQUICK, India’s first biosimilar Insulin Aspart, which will improve access for people with diabetes.

InsuQuick is a “Make in India” product, developed and manufactured using 100% indigenous technology, and has undergone a robust clinical programme to ensure global quality standards. It is available in all metros, and Tier I/II cities.

Prashant Tewari, Managing Director, USV, said," Our entry into injectables is a strategic step towards bolstering our market presence and our aspiration to lead in the diabetes market. We have collaborated with Biogenomics to provide global-quality insulin aspart for our people with diabetes.

Dr Sanjay Sonar, Co-Founder and President of Biogenomics, said, “Insulin aspart is the first biosimilar in the category of rapid-acting insulin and is a result of more than ten years of R&D efforts.

Insuquick will be available in cartridges, vials, and prefilled disposable pens, offering flexibility tailored to the needs of people with diabetes. The disposable and reusable pens are contemporary and lightweight in design and have a legible scale and audible clicks for precise incremental settings.

Insulin Aspart is intended to be the stepping stone for USV’s entry into the insulin market. The company will continue to expand in the coming years with robust R&D to deliver comprehensive solutions to people with diabetes.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account